Original Article

You have full text access to this OnlineOpen article

Measuring the side effects of taxane therapy in oncology

The Functional Assessment of Cancer Therapy–taxane (FACT-taxane)

  1. David Cella Ph.D.1,†,*,
  2. Amy Peterman Ph.D.1,
  3. Stacie Hudgens M.A.1,
  4. Kimberly Webster M.A.1,
  5. Mark A. Socinski M.D.2

Article first published online: 20 JUN 2003

DOI: 10.1002/cncr.11578

Issue

Cancer

Cancer

Volume 98, Issue 4, pages 822–831, 15 August 2003

Additional Information

How to Cite

Cella, D., Peterman, A., Hudgens, S., Webster, K. and Socinski, M. A. (2003), Measuring the side effects of taxane therapy in oncology. Cancer, 98: 822–831. doi: 10.1002/cncr.11578

Author Information

  1. 1

    Center on Outcomes, Research and Education (CORE), Evanston Northwestern Healthcare, and Northwestern University, Evanston, Illinois

  2. 2

    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina

  1. †

    Fax: (847) 570-8033

*Center on Outcomes, Research and Education (CORE), Evanston Northwestern Healthcare, 1001 University Place, Suite 100, Evanston, IL 60201

Publication History

  1. Issue published online: 1 AUG 2003
  2. Article first published online: 20 JUN 2003
  3. Manuscript Accepted: 9 MAY 2003
  4. Manuscript Revised: 21 APR 2003
  5. Manuscript Received: 5 FEB 2003

Funded by

  • Bristol Myers-Squibb
  • Pharmacia
  • Astra-Zeneca
  • Aventis Pharmaceuticals

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (110K)

REFERENCES

  • 1
    Rowinsky EK, Donehower RC. Drug therapy: Paclitaxel (Taxol). N Engl J Med. 1995; 332: 1004–1014.
  • 2
    Tankanow RM. Docetaxel: a taxoid for the treatment of metastatic breast cancer. Am J Health Syst Pharm. 1998; 55: 1777–1791.
  • 3
    Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature. 1979; 277: 665–667.
  • 4
    Schiff PB, Horwitz SG. Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci U S A. 1980; 82: 1247–1259.
  • 5
    Rowinsky EK, Cazenave LA, Donehower R. Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst. 1990; 82: 1247–1259.
  • 6
    Pronk LC, Stoter G, Verweij J. Docetaxel (Taxotere): single agent activity, development of combination treatment and reducing side effects. Cancer Treatment Rev. 1995; 21: 463–478.
  • 7
    Lavelle F, Bissery MC, Combeau C, et al. Preclinical evaluation of docetaxel (Taxotere). Semin Oncol. 1995; 22(Suppl 4): 3–16.
  • 8
    von Minckwitz G, Costa SD, Raab G, et al. Dose-dense doxorubicin, docetaxel, and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: a randomized controlled open phase IIb study. J Clin Oncol. 2001; 19: 3506–3515.
  • 9
    Hinton S, Catalano P, Einhorn LH, et al. Phase II study of paclitaxel plus gemcitabine in refractory germ cell tumors (E9897): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2002; 20: 1859–1863.
  • 10
    Kosmidis P, Mylonakis N, Nicolaides C, et al. Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small cell lung cancer: a phase III randomized trial. J Clin Oncol. 2002; 20: 3578–3585.
  • 11
    Loesch D, Robert N, Asmar L, et al. Phase II multicenter trial of a weekly paclitaxel and carboplatin regimen in patients with advanced breast cancer. J Clin Oncol. 2002; 20: 3857–3864.
  • 12
    Markman M, Hall J, Spitz D, et al. Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer. J Clin Oncol. 2002; 20: 2365–2369.
  • 13
    Choy H, Shur Y, Cmelak AJ, Mohr PJ, Johnson DH. Patterns of practice survey for non-small cell lung cancer in the U.S. Cancer. 2000; 88: 1336–1346.
    Direct Link:
  • 14
    Forsyth PA, Balmaceda C, Peterson K, et al. Prospective study of paclitaxel-induced peripheral neuropathy with quantitative sensory testing. J Neurooncol. 1997; 35: 47–53.
  • 15
    Socinski MA, Schell MJ, Peterman A, et al. Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced stage IIIB/IV non-small-cell lung cancer. J Clin Oncol. 2002; 20: 1335–1343.
  • 16
    Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy Scale: development and validation of the general measure. J Clin Oncol. 1993; 11: 570–579.
  • 17
    Calhoun EA, Fishman DA, Roland PY, et al. Validity and sensitivity of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group–Neurotoxicity (FACT/GOG-Ntx). Proc Am Soc Clin Oncol. 2000; 19: 446a.
  • 18
    Cella D, Bonomi A, Lloyd SR, Tulsky DS, Kaplan E, Bonomi P. Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument. Lung Cancer. 1995; 12: 199–220.
  • 19
    Cohen J. Statistical power analysis for the behavioral sciences, 2nd edition. Hillsdale, NJ: Lawrence Erlbaum Associates, Publishers, 1988.
  • 20
    Cella D, Eton DT, Fairclough DL, et al. What is a clinically meaningful change on the Functional Assessment of Cancer Therapy–Lung (FACT-L) questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) Study 5592. J Clin Epidemiol. 2002; 55: 285–295.
  • 21
    Wyrwich K, Tierney W, Wolinsky F. Further evidence supporting an SEM-based criterion for identifying meaningful intra-individual changes in health-related quality of life. J Clin Epidemiol. 1999; 52: 861–873.
  • 22
    Bennett KJ, Torrance GW. Measuring health state preferences and utilities: rating scale, time trade off and standard gamble techniques. In: SpilkerB, editor. Quality of life and pharmacoeconomics in clinical trials, 2nd edition. Philadelphia: Lippincott-Raven, 1996: 253–265.
  • 23
    Fairclough DL, Peterson H, Cella D, Bonomi P. Comparison of several model-based methods for analyzing incomplete quality of life data in cancer clinical trials. Stat Med. 1998; 17: 781–796.
    Direct Link:
  • 24
    Hahn EA, Webster KA, Cella D, Fairclough DL. Missing data in quality of life research in Eastern Cooperative Oncology Group (ECOG) clinical trials: problems and solutions. Stat Med. 1998; 17: 547–559.
    Direct Link:
View Full Article (HTML) Get PDF (110K)